Shionogi Stays The Course As It Lays Out R&D Priorities
Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.
Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.